H. Lundbeck A/S Class A HLUN_A

Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar with the matter cited by Bloomberg. The Danish pharmaceutical group has been working with financial advisers to explore an acquisition of the U.S. firm, though discussions remain preliminary and may not result in a formal transaction.

H. Lundbeck (CPSE:HLUN B) has just secured Japanese marketing authorization for eptinezumab in migraine prevention, a fresh regulatory milestone that broadens its neuroscience footprint and adds another data point for investors watching the stock. The eptinezumab approval lands at a time when H. Lundbeck’s recent news flow also includes the randomization milestone in its Phase III bexicaserin epilepsy program and a plan to shift its US base to Greater Boston to build out a global innovation...

Vyepti and Rexulti lead strong H1 performance, while the company navigates competitive pressures and prepares for key Phase III readouts.

H. Lundbeck AS (HLUBF) reports robust financial performance with double-digit growth in strategic brands and a strengthened pipeline.

We recently published 10 Market Movers That Made Millionaires in a Week. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the best-performing stocks of the past trading week. Avadel jumped by 26.06 percent week-on-week as investors loaded up portfolios after receiving a new takeover interest from a new pharmaceutical giant. Last Friday, Avadel Pharmaceuticals plc (NASDAQ:AVDL) […]

We recently published Lackluster Market? Not for These 10 Soaring Stocks. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the best-performing stocks on Friday. Avadel extended its winning streak to a 5th straight day on Friday to hit a new 10-year high as investor sentiment was boosted by its receipt of a new acquisition proposal which […]

H. Lundbeck AS (HLUBF) reports strong revenue growth and upgrades full-year guidance amid strategic investments and market challenges.